2-[(2-oxopropyl)thio] imidazolium derivates

1,3,4,5-Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride



Order
Quantity
Price
Status
10 mg 480 € available


Documents
Art. No. T101
Synonym L-682.777, SU732
Molecular Formula C10H17N2OS+Cl-
Molecular Weight 248,77
Purity by HPLC > 95% (HPLC)
Appearance off white solid
Solubility 50 mM in aqueous buffers
Dissolve e.g. 5.0 mg in 402 μl PBS buffer to obtain a 50 mM solution
or: 50 μM in 0.1% (v/v) DMSO / aqueous buffers.
Pre-dissolve e.g. 10.0 mg in 804 μl DMSO (50 mM).
Take e.g. 10 μl of the 50 mM stock solution - dilute by adding 9990 μl buffer or assay components to obtain your final assay solution (50 μM).
DMSO stock solutions are sterile and can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Inhibitor for transglutaminase.
The molecule was developed to block coagulation factor XIIIa, however the compound inhibits tissue transglutaminase as well. Both enzymes are inhibited with an IC50 of about 0.25 μM.
Storage Store at -20°C
Reference(s) Freund, K.F. et al. Biochemistry 1994, 33, 10109.
Lorand, L. et al. Exp. Eye Res. 1998, 66, 531.
Dale, G.L. et al. Nature 2002, 415, 175.
Dodt, J. et al. Anal. Biochem. 2013, 439, 145.
v.d. Akker J. et al. PLoS One 2011, 6, e23067.
Matlung, H.L. et al. Atherosclerosis 2010, 213, 77.
Barsigan C. et al., J. Biol. Chem. 1991, 266, 22501.
Katt, P.W. et al. Mol. Pharmaceutics 2015, 12, 46-55.
Aleman, M.M. et al. J. Clin. Invest. 2014, 124, 3590.
Aleman, M.M. et al. PLoS ONE 2015, 10, e0124448.
Kattula, S. et al. Blood Adv. 2018, 2, 25-35.
Macrae, F.L. et al. Clin Invest. 2018, 128, 3356-3368.
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageZedira ISO9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    12.11.2019
    Düsseldorf, Germany

  • New Frontiers Symposium

    23.11.2019
    Chicago, USA

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA